0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Moments in Surgical History |

Siegfried Oberndorfer and the Evolution of Carcinoid Disease

Irvin M. Modlin, MD, PhD; Michael D. Shapiro, MD; Mark Kidd, PhD; Geeta Eick, PhD
Arch Surg. 2007;142(2):187-197. doi:10.1001/archsurg.142.2.187.
Text Size: A A A
Published online

Siegfried Oberndorfer was born in Munich, Germany, in 1876, studied medicine at the University of Munich, and became the youngest Jewish physician to be appointed to its faculty (1907). His unique observations regarding multiple small-intestinal tumors were presented at the German Pathological Society convention (Dresden, Germany, September 1907), where he coined the term karzinoide and published it in December of the same year. Twenty-two years later (in 1929), he amended this report and suggested that carcinoid tumors might also exhibit malignant features and metastasize. The rise of Nazism led to the termination of his position in 1933, and he “emigrated” to Turkey to serve as the chair of anatomical pathology at the University of Istanbul, Istanbul, Turkey, where he remained until his death in 1944. This exploration of his life and times seeks to give Oberndorfer his well-deserved place in the pantheon of pathology and memorialize his unique observations that led to the discovery of the carcinoid tumor.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Place holder to copy figure label and caption
Figure 1.

In September 1907, Siegfried Oberndorfer presented his seminal work on carcinoid tumors at the German Pathological Society meeting in Dresden, Germany, and 3 months later it was published in the Frankfurt Journal of Pathology (frontispiece, top right). He described 6 cases of ileal tumors that grew extremely slowly and did not appear to metastasize. On recognizing that these tumors represented a novel disease entity, he ascribed a name to describe the nature of these tumors, karzinoide, or carcinomalike.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

A timeline of the evolution of the diagnosis and management of carcinoid tumor disease. WHO indicates World Health Organization; APUD, amine precursor uptake and decarboxylation; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; EC, enterochromaffin; ECL, enterochromaffin-like.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Theodor Langhans (1839-1915) (top left) published the first report (1867) of a carcinoid tumor (frontispiece, bottom left). Otto Lubarsch (1860-1933) (bottom right) provided the first detailed pathological description (top right) of carcinoid tumors (1888).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Pierre Masson (top right) and Andre Gosset (top left) demonstrated the argentaffin staining properties of carcinoid tumors (frontispiece, top) and proposed that the enterochromaffin cells in the gut formed a diffuse endocrine organ. The first description of this diffuse neuroendocrine system was provided in 1938 by Friedrich Feyrter (bottom right).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 5.

Siegfried Oberndorfer was responsible for the planning and development of the new Pathological Institute of the Munich-Schwabing Hospital, which he described in 1912 (frontispiece, bottom; floor plan, background). From 1911 to 1933, he served as professor and chair of the Pathological Institute, and in 1915, he served Germany during World War I as an army pathologist (center).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 6.

In 1933, Siegfried Oberndorfer's career was summarily terminated when the National Socialist German Workers' Party orchestrated the boycott of all Jewish physicians. Kemal Pascha (“Atatürk”) (top center) retained Albert Malche, the former Swiss minister of education, to assist in the reformation of the Turkish University system. To this end, Malche undertook the recruitment of the academic elite purged from German universities; by the close of the war, the University of Istanbul was considered the best German university in the world. In 1933, Malche sent an invitation (top left) to Oberndorfer to serve as chair of general and experimental pathology at the University of Istanbul, where he initially delivered his lectures in German with a translator by his side (bottom right).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 7.

Siegfried Oberndorfer (top right) died in 1944 at the age of 67 years and was buried at the Sisli cemetery in Istanbul (bottom left). The original autopsy report (background) indicated the cause of death to be a mediastinal mass; in 2004, reexamination of the original tumor specimen at the Yale University School of Medicine confirmed the tumor to be a thymoma (center).

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 8

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();